| Sponsored by: |
| The International Society For Antiviral Research |
| At the Westin Mission Hills Resort |
| Palm Springs, CA, USA |
| April 29–May 3, 2007 |
| Table of Contents | |
| Page | |
| Organization and Conference Committees | |
| Organizing Secretariats, Introduction To Sponsor | |
| Corporate Sponsors | |
| Satellite Symposium, Social Functions | |
| Scientific Program | |
| Monday, April 30, 2007 | |
| Oral Session I: Retroviruses I | |
| Oral Session II: Respiratory and West Nile Viruses | |
| Poster Session I: Retroviruses, Respiratory Viruses, West Nile Virus, Hepatitis Viruses, and Antiviral Methods | |
| Tuesday, May 1, 2007 | |
| Mini-Symposium: Hepatitis C Virus: Translating Research to Medicine | |
| Wednesday, May 2, 2007 | |
| Oral Session III: Herpesviruses I and Poxviruses I | |
| Invitation to 21st ICAR, ISAR Business Meeting | |
| Oral Session IV: Hepatitis Viruses I | |
| Poster Session II: Herpesviruses, Poxviruses, other Antivirals, and Medicinal Chemistry | |
| Thursday May 3, 2007 | |
| Oral Session V: Hepatitis Viruses II, Herpesviruses II and Poxviruses II | |
| Oral Session VI: Other Viruses and Late Breaker Presentations | |
| Abstracts | |
| Complete Author Index | |
| Invitation to the 21th International Conference on Antiviral Research | |
| Locations for Future International Conferences on Antiviral Research | |
| Organization |
| International Society for Antiviral Research |
| and |
| Twentieth International Conference on Antiviral Research |
| Officers |
| President—Christopher McGuigan, Cardiff, Wales, UK |
| President-Elect—Amy K. Patick, San Diego, California, USA |
| Secretary—Joseph Colacino, South Plainfield, New Jersey, USA |
| Treasurer—John D. Morrey, Logan, Utah, USA |
| Past President—John A. Secrist III, Birmingham, Alabama, USA |
| ISAR Conference Committee |
| Chair: John A. Secrist III, Birmingham, Alabama, USA |
| Karen K. Biron, Research Triangle Park, North Carolina, USA |
| Robert W. Buckheit, Frederick, Maryland, USA |
| Erik DeClercq, Leuven, Belgium |
| John C. Drach, Ann Arbor, Michigan, USA |
| José A. Esté, Barcelona, Spain |
| A. Kirk Field, North Wales, Pennsylvania, USA |
| George J. Galasso, Rockville, Maryland, USA |
| Paul D. Griffiths, London, UK |
| John D. Morrey, Logan, Utah, USA |
| Robert W. Sidwell, Logan, Utah, USA |
| Leroy B. Townsend, Sedona, Arizona, USA |
| Organizing Secretariats | |
| Courtesy Associates | John A. Secrist III |
| 2025 M Street, NW | Southern Research Institute |
| Suite 800 | P.O. Box 55305 |
| Washington, DC 20036 | Birmingham, AL 35255-5305 |
| USA | USA |
| Phone: +1 202 973 8690 | Phone: +1 205 581 2442 |
| Fax: +1 202 331 0111 | Fax: +1 205 581 2870 |
| E-mail: isar@courtesyassoc.com | E-mail: Secrist@sri.org |
| Introduction To Sponsor |
| The International Society For Antiviral Research (ISAR) |
The Society was organized in 1987 as a non-profit scientific organization for the purpose of advancing and disseminating knowledge in all areas of antiviral research. To achieve this objective, the Society organizes an annual meeting. The Society is now in its twenty first year of existence, and has about 600 members representing 30 countries. For membership application forms or further information, please contact Dr. Joseph M. Colacino, Secretary, ISAR; Vice President, Drug Discovery, PTC Therapeutics, Inc., 100 Corporate Court, south Plainfield, NJ 07080, USA, Phone +1 908 222 7000x131; fax +1 908 222 0567; E-mail jcolacin0@ptcbio.com. Membership application forms will also be available at the Conference Registration desk, or from our website http://m114.phrm.cf.ac.uk/isar/node/1.
| Platinum |
| Gilead Sciences Inc., Foster City, CA, USA |
| Gold |
| JCR Pharmaceuticals Co. Ltd., Ashiya, Japan |
| Pfizer, Inc., New York, NY, USA |
| Silver |
| Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA |
| GlaxoSmithKline, Research Triangle Park, NC, USA |
| Bronze |
| Abbott Laboratories, Abbott Park, IL, USA |
| Biota, Melbourne, Victoria, Australia |
| Boehringer Ingelheim (Canada) Ltd., Laval, Quebec, Canada |
| Bristol-Myers Squibb Pharmaceuticals Institute, Princeton, NJ, USA |
| Debiopharm Group, Lausanne, Switzerland |
| Medimmune, Inc., Gaithersburg, MD, USA |
| Medivir AB, Huddinge, Sweden |
| Merck Research Laboratories, West Point, PA, USA |
| Pharmasset, Inc., Princeton, NJ, USA |
| PTC Therapeutics Inc., South Plainfield, NJ, USA |
| Southern Research Institute, Birmingham, AL, USA |
| Vertex Pharmaceuticals Inc., Cambridge, MA, USA |
| Wyeth Research, Pearl River, NY, USA |
| Additional Support Provided by: |
| Office of AIDS Research, National Institutes of Health, Bethesda, MD, USA |
| SATELLITE SYMPOSIUM |
| Clinical Update on Antiviral Drugs |
| Sunday, April 29, 2007 |
| 2:00–5:00 p.m. |
| Celebrity Ballroom EFGH |
| Westin Mission Hills Resort |
| SOCIAL EVENTS |
| Opening Reception |
| with light hors d’oeuvres |
| Sunday, April 29, 2007 |
| 6:00–8:00 p.m. |
| Masters Plaza |
| Westin Mission Hills Resort |
| Conference Banquet |
| Wednesday, May 2, 2007 |
| Reception |
| 7:30 p.m. |
| Celebrity Foyer and Plazas |
| Westin Mission Hills Resort |
| Dinner and Program |
| 8:00–10:00 p.m. |
| Celebrity Ballroom EFGH |
| Westin Mission Hills Resort |
| Final Program |
| Twentieth International Conference on Antiviral Research |
| Sponsored by the |
| International Society for Antiviral Research |
| At the Westin Mission Hills Resort |
| Palm Springs, California |
| April 29–May 3, 2007 |
| 2007 International Conference on Antiviral Research | ||
| Monday, April 30, 2007 | ||
| Opening Greetings | ||
| Celebrity Ballroom EFGH | ||
| Welcome to the 20th ICAR, Christopher McGuigan, President ISAR | ||
| Welcome to Palm Springs, John A. Secrist III, Chair, ICAR Conference Committee | ||
| Oral Session I: Retrovirus I | ||
| Celebrity Ballroom EFGH | ||
| Chairs: Wade Blair, Ph.D. and Masanori Baba, Ph.D. | ||
| 08:45 | Plenary Speaker | |
| Daria Hazuda, Ph.D., Vice President, Merck Research Laboratories, West Point, PA, USA | ||
| “Inhibitors of HIV-1 Integrase: Lessons from In Vivo, Preclinical, and Clinical Studies” | ||
| 09:15 | 1. | Identification of a Novel Small Molecule Inhibitor that Targets HIV-1 Envelope Maturation |
| Judith Jimenez, Joan Cao, Lynn Jackson, Qinghai Peng, Hua Wu, Jason Isaacson, Scott Butler, Amy K. Patick, Wade S. Blair | ||
| Pfizer Global Research and Development (La Jolla, CA, USA) | ||
| 09:30 | 2. | GS-8374, a Novel Phosphonate HIV Protease Inhibitor with Potent In Vitro Antiretroviral Activity, Low Metabolic Toxicity, and Favorable Resistance Profile |
| Christian Callebaut1, Kirsten Stray1, Luong Tsai1, Lianhong Xu1, Gong-Xin He1, Andrew Mulato1, Tina Priskich2, Neil Parkin2, William Lee1, Tomas Cihlar1 | ||
| 1Gilead Sciences, Foster City, CA, USA; 2Monogram Biosciences, S. San Francisco, CA, USA | ||
| 09:45 | 3. | The CXCR4 Antagonist POL3026 is a Potent Inhibitor of Human Immunodeficiency Virus |
| Gemma Moncunill1, Imma Clotet-Codina1, Anuska LLano1, Mercedes Armand-Ugón1, Bonaventura Clotet1, Jan Willem Vrijbloed2, José A. Esté1 | ||
| 1Retrovirology Laboratory IrsiCaixa and AIDS Unit, Hospital Germans Trias i Pujol, 08916 Badalona, Spain; 2Polyphor Ltd., Basel, Switzerland | ||
| 10:00 | Break | |
| 10:30 | 4. | Mutations in the RNaseH Region Observed in the HIV-1 of Antiretroviral Treatment (ART) Experienced Patients |
| J. Waters1, W. O’Neal1, K. White2, E. Lansdon2, M. Miller2, J. Harris1, K. Borroto-Esoda1 | ||
| 1Gilead Sciences, Durham, NC, USA; 2Gilead Sciences, Foster City, CA, USA | ||
| 10:45 | 5. | Involvement of New Mutational Pattern in HIV-1 gp41 in T-20 Treatment |
| Stefano Aquaro1,2, Valentina Svicher2, Roberta D’Arrigo3, Mario Santoro2, Giovanni Di Perri4, Sergio Lo Caputo5, Ubaldo Visco-Comandini3, Pasquale Narciso3, Andrea Antinori3, Carlo Federico Perno3 | ||
| 1University of Calabria, Rende (CS), Italy; 2University “Tor Vergata”, Rome, Italy; 3“L Spallanzani” Institute, Rome, Italy; 4University of Turin, Italy; 5“SM Annunziata” Hospital, Florence, Italy | ||
| 11:00 | 6. | Drug Resistance to Tipranavir (TPV) or Darunavir (DRV) According to New Interpretation Algorithms in PI-naïve HIV-1 Infected Patients |
| M. Stuermer1, B. Dauer1, A. Haberl1, A. Mueller1, P. Gute2, S. Klauke3, S. Staszewski1, H.W. Doerr1 | ||
| 1JWG-University Hospital, Frankfurt, Germany; 2HIV Specialty Practice, Frankfurt, Germany; 3IFS, Frankfurt, Germany | ||
| 11:15 | 7. | HIV Interactions With Other Viruses Determine Pathogenesis in Human Lymphoid Tissues |
| Leonid Margolis | ||
| National Institute of Child Health and Human Development | ||
| 11:30 | Lunch | |
| Elion Award Lecture | ||
| Celebrity Ballroom EFGH | ||
| 13:30 | Presentation of Award: Christopher McGuigan, Ph.D., President ISAR | |
| Awardee lecture: Frederick Hayden, MD, USA, Medical Officer, World Health Organization, Geneva, Switzerland | ||
| “Influenza: Progress, Problems, and Future Prospects” | ||
| Oral Session II: Respiratory and West Nile Viruses | ||
| Celebrity Ballroom EFGH | ||
| Chairs: Colleen Jonsson, Ph.D. and Don Smee, Ph.D. | ||
| 14:15 | 8. | Identification and Biochemical Characterization of Small Molecule Inhibitors of West Nile Virus Serine Protease By A High Throughput Screen |
| Radhakris Padmanabhan1, Niklaus Mueller1, Nagarajan Pattabiraman2 | ||
| 1Department of Microbiology and Immunology, Georgetown University; 2Biomids Inc. | ||
| 14:30 | 9. | Discovery of a New Class of Polycyclic RSV Inhibitors |
| Silas Bond1, Alistair Draffan1, John Lambert1, Chin-Yu Lim1, Bo Lin1, Angela Luttick1, Jeff Mitchell1, Craig Morton1, Roland Nearn1, Vanessa Sanford1, Simon Tucker1 | ||
| 1Biota Holdings Limited; 2MedImmune Inc. | ||
| 14:45 | 10. | Potent Inhibition of Viral Entry and Replication of SARS-CoV by siRNAs Targeting the Genes Encoding the Cellular ACE2 Receptor or the Viral Nucleocapsid Protein |
| Xin Yan1,2,3, Hua Shen2, Yan Feng1, Jun Wang2, Shiwen Lou4, Liping Wang5, Gillian Wong1, Zhaoxiong Yang2, Hongjian Jiang6, Xinqi Wu6, Dan Hu5, Yi Guan4, Fiona Smaill1, Chengsheng Zhang1 | ||
| 1Department of Pathology & Molecular Medicine, McMaster University, Canada; 2New Medical Science Research Institute, New York, USA; 3Institute of Chongqing Traditional Chinese Medicine, Chongqing, China; 4Department of Microbiology, University of Hong Kong, Hong Kong; 5Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA; 6Children's Hospital, Harvard Medical School, Boston, USA | ||
| 15:00 | 11. | Thiazolides: A New Class of Broad-Spectrum Antiviral Drugs Targeting Virus Maturation |
| M. Gabriella Santoro1, Alessandra Ciucci1, Patrizia Gianferretti1, Giuseppe Belardo1, Simone La Frazia1, Stefania Carta1, Jean-Francois Rossignol2 | ||
| 1Department of Biology, University of Rome Tor Vergata, Rome, Italy; 2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA | ||
| 15:15 | 12. | Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in Mice |
| Natalia A. Ilyushina, Robert G. Webster, Elena A. Govorkova | ||
| St. Jude Children's Research Hospital, Memphis, TN 38105, USA | ||
| 15:30 | 13. | Intramuscular Administration of Neuraminidase Inhibitor Peramivir Promotes Survival Against Lethal H5N1 Influenza Infection in Mice |
| David A. Boltz1, Natalia A. Ilyushina1, C. Shane Arnold2, Y. Sudhakar Babu2, Robert G. Webster1, Elena A. Govorkova1 | ||
| 1St Jude Children's Research Hospital, Memphis, TN 38105, USA; 2BioCryst Pharmaceuticals, Inc., Birmingham, AL 35244, USA | ||
| 15:45 | 14. | Treatment of Paralysis Caused by West Nile Virus in Hamsters |
| John D. Morrey1, Venkatraman Siddharthan1, Hong Wang1, Aaron L. Olsen1, Ramona Skirpstunas1, Jeffery O. Hall1, Hua Li2, Scott Koenig2, Syd Johnson2, Jeffrey L. Nordstrom2, Nicole Marlenee3, Richard A. Bowen3, Michael S. Diamond4 | ||
| 1Institute for Antiviral Research, ADVS Depart, Utah State Univ, USA; 2Macrogenics, Inc.; 3Depart of Biomed Sci, Colorado State Univ; 4Depart of Mol Micro, Medicine, and Pathol & Immunol, Washington Univ, St. Loius | ||
| Poster Session I: Retrovirus, Respiratory Virus, West Nile Virus and Hepatitis Virus, and Antiviral Methods | |
| Celebrity Ballroom ABCD | |
| 16:00–18:00 | |
| 43. | Intranasal Protollin Formulated Recombinant SARS-CoV S Protein Elicits Respiratory and Serum Neutralizing Antibodies Dale Barnard1, Mary Hu2, Taff Jones3, Richard Kenney4, David Burt3, George Lowell3 |
| 1Institute for Antiviral Research, Dept. ADVS, Utah State University; 2GlaxoSmithKline Biologicals North America of Washington; 3GlaxoSmithKline Biologicals North America of Quebec; 4GlaxoSmithKline Biologicals North America of Maryland | |
| 44. | Bile Acid Conjugates Improve the Oral Bioavailability of the Neurominidase Inhibitor Zanamivir |
| Phillip Kish1, Jae Seung Kim1, Blake Roessler2, Shelby Campbell1, John Hilfinger1 | |
| 1TSRL, Inc. Ann Arbor, MI 48108; 2University of Michigan, Dept of Internal Medicine, Ann Arbor 48109, USA | |
| 45. | Lymphocytic Necrosis in Hamsters Inoculated with Western Equine Encephalitis Virus |
| Aaron Olsen1, John Morrey1, Justin Julander1, Jeffery Hall2, Ramona Skirpstunas2, Robert Sidwell1 | |
| 1Institute for Antiviral Research, Utah State University; 2Utah Veterinary Diagnostic Laboratory, Utah State University | |
| 46. | Combined Anti-Influenza Virus Effect of a Plant Polyphenol-Rich Extract and Ribavirin |
| Julia Serkedjieva, Ani Teodosieva | |
| Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria | |
| 47. | Anti-influenza A Synergistic Combination Effect of Rimantadine and Oseltamivir in Mice |
| Lora Simeonova, Angel S. Galabov, Galina Gegova | |
| The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, BG-1113, Sofia, Bulgaria | |
| 48. | Phosphorodiamidate Morpholino Oligomer-Mediated Inhibition of Influenza A Virus in Mice |
| Thomas Voss2, Kelly Warfield3, Rebecca Brocato2, Joseph Barbercheck2, Bryan Kaplin2, David Stein1, Sina Bavari1, Patrick Iversen1 | |
| 1AVI BioPharma Inc., 4575 SW Research Way, Corvallis, OR 97333, USA; 2Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans 70112 LA, USA; 3US Army Medical Research Institute for Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA | |
| 49. | Practical Synthesis of (−)-Carbocyclic Cytosine (Carbodine) and its In Vitro Antiviral Activity against Venezuelan Equine Encephalitis (VEE) Virus and Yellow Fever Virus |
| J. R. Rao1, J. G. Julander2, R. W. Sidwell2, C. K. Chu1 | |
| 1The University of Georgia College of Pharmacy, Athens, GA, 30602, USA; 2Utah State University Institute Antiviral Research, Logan, UT 84322, USA | |
| 50. | Synthesis, Anti-HIV and CD4 Down-Modulation Activities of Novel CADA Compounds |
| Sreenivasa Anugu1, Thomas Bell1, Noah Duffy1, Kurt Vermeire2, Dominique Schols2 | |
| 1Department of Chemistry, University of Nevada, Reno, NV, 89557, USA; 2Rega Institute for Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium | |
| 51. | Synthesis and Antiviral Evaluation of Iso-methyl-alkoxyalkyl (S)-HPMPA Esters |
| James R. Beadle1, Karl Y. Hostetler1, R. Mark Buller2, Jill Schriewer2, Kathy A. Aldern1, Mark N. Prichard3, Kathy Keith3, Earl R. Kern3 | |
| 1University of California, San Diego and the San Diego Veterans Medical Research Foundation, San Diego, CA, USA; 2Department of Molecular Microbiology and Immunology, Saint Louis University, St. Louis, MO, USA; 3Department of Pediatrics, University of Alabama School of Medicine, Birmingham, AL, USA | |
| 52. | Raft-tropic Antivirals: 1. Synthesis and anti-HIV-1 Evaluation of Cholesten-containing Polyanios |
| Y. Egorov, A. Serbin, O. Alikhanova, M. Burshtein, S. Lupandin, A. Bukrinskaya | |
| Health RDF, Moscow, Russia | |
| 53. | 7-Deaza Neplanocin Analogs Inhibit Hepatitis C Virus (HCV) in Vitro |
| HJ Kim1, JN Wang1, ZH Huang2, MG Murray2, RF Schinazi3, CK Chu1 | |
| 1The University of Georgia College of Pharmacy; 2Southern Research Institute; 3Emory University School of Medicine/ Veterans Affairs Medical Center | |
| 54. | QSAR Analysis of Anti-Coxsackievirus B3 Nancy Activity of 2-Amino-3-Nitropyrazole[1,5-α]Pyrimidines by Means of Simplex Approach |
| V. Kuz’min1,2, E. Muratov1,2, A. Artemenko2, I. Volineckaya2, V. Makarov3, O. Riabova3, P. Wutzler4, M. Schmidtke4 | |
| 1Jackson State University, Jackson, MS, USA; 2A.V. Bogatsky Physical-Chemical Institute, Odessa, Ukraine; 3Research Center for Antibiotics, Moscow, Russia; 4Institute of Virology and Antiviral Therapy, Friedrich Schiller University, Jena, Germany | |
| 55. | The Design, Synthesis and Anti-HIV Activity of a selected group of 2′,3′-didehydro-2′,3′-dideoxyguanosine (d4G) and 2′,3′-dideoxyguanosine (ddG) ‘ProTide’ Derivatives |
| Youcef Mehellou1, Christopher McGuigan1, Jan Balzarini2 | |
| 1Welash School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK; 2Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium | |
| 56. | Novel Diketo Phosphonic Acids Constructed on Nucleobase Scaffolds: Design, Synthesis, Molecular Modeling and anti-HIV Activity |
| Vasu Nair, Guochen Chi, Iwona Dams, Byung Seo, Vinod Uchil, Arthur Cox | |
| Center for Drug Discovery and Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA | |
| 57. | Design, Synthesis, Anti-Hiv and Cytotoxicity of Novel Heterocyclic Compounds |
| Periyasamy Selvam1, Narayanan Murugesh2, Markandavel Chandramohan3, Erik De Clercq4, Christophe Pannecouque4 | |
| 1Arulmigu Kalasalingam College of Pharmacy, Anand nagar, Krishnankoil 626190, India; 2Institute of Pharmacology, Madurai Medical College, Madurai 625020, India; 3Bharat Ratna Kamarajar Liver Hospital and Research Centre, Madurai 625001, India; 4Rega institute of medical research, Katholieke Universiteit Leuven, Belgium | |
| 58. | Poly-Cooperation of Ionic and Non-Ionic Antiviral Vectors |
| A. Serbin, Y. Egorov, O. Alikhanova | |
| Health RDF, Moscow, Russia | |
| 59. | Potent HCV NS5B Polymerase Inhibitors Derived From 5-Hydroxy-3(2H)-Pyridazinones: Part 2. Variation of the 2- and 6- Pyridazinone Substituents |
| Y. Zhou, L.-S. Li, S. Webber, B. Ayida, T. Bertolini, Z. Sun, J. Zhao, N. Stankovic, R. Patel, B. Li, L. LeBrun, R. Kamran, M. Sergeeva, D. Bartkowski, J. Khandurina | |
| Anadys Pharmaceuticals, Inc., San Diego, CA, USA | |
| 60. | Synthesis of Novel Types of Anti-Coxsackie Virus Compounds |
| Michal Šála1, Hubert Hřebabecký1, Martin Dračínský1, Armando De Palma2, Johan Neyts2, Antonín Holý1 | |
| 1Centre for New Antivirals and Antineoplastics, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 166 10 Prague 6, Czech Republic; 2Rega Institute for Medical Research, Minderbroedersstraat 10, BE-3000, Leuven, Belgium | |
| 61. | Metabolism and Pharmacokinetic Studies of SB 9000—A Novel Anti-HBV agent |
| John Coughlin, Seetharamaiyer Padmanabhan, Radhakrishnan Iyer | |
| Spring Bank Technologies, Inc., 113, Cedar Street, Suite S-7, Milford, MA 01757, USA | |
| kiyer@springbanktech.com | |
| 62. | Neutralizing Human Antibodies from Immune Phage Display Antibody Library Recognize p35 Orthopoxvirus Protein |
| Viktoriya Dubrovskaya, Belanov Evgeniy, Bormotov Nikolay, Tikunova Nina | |
| FSRI SRC VB “Vector” | |
| 63. | New Digital Method of Virus-Cell Interaction Description |
| Andriy Fedchuk1, Oleksandr Fedchuk1, Alla Fedchuk2, Pavlo Fedchuk3 | |
| 1I.I. Mechnikov Odesa National University; 2I.I. Mechnikov Ukrainian Research Anti-Plague Institute; 3Odesa State Academy of Refrigeration | |
| 64. | Fractal Microscope—Multipurpose Device For Antiviral Research |
| Oleksandr Fedchuk1, Andriy Fedchuk1, Alla Fedchuk2, Pavlo Fedchuk3 | |
| 1I.I. Mechnikov Odesa National University; 2I.I. Mechnikov Ukrainian Research Anti-Plague Institute; 3Odesa State Academy of Refrigeration | |
| 65. | Sublingual Delivery of SB 9000—An Anti-HBV Dinucleoside Phosphorothioate Analog |
| Radhakrishnan Iyer1, Padma Devarajan2, Sayalee Shastri2, Swati Guhagarkar2, Rita Mulherkar3, Ganesh Joshi3, Seetharamaiyer Padmanabhan1, John Coughlin1 | |
| 1Spring Bank Technologies, Inc., 113 Cedar Street, Milford, MA 01757, USA; 2University Institute of Chemical Technology, Matunga, Mumbai 40019, India; 3Tata Memorial Centre, Advanced Centre for Treatment, Research, and Education in Cancer, Navi Mumbai 410208, India | |
| 66. | Initial Pharmacodynamic Evaluation of Orally Bioavailable Prodrugs of SB-9000, a Novel Anti-HBV Agent |
| Radhakrishnan Iyer1, Seetharamaiyer Padmanabhan1, John Coughlin1, Guangrong Zhang1, Cassandra Kirk1, Brent Korba2, John Morrey3 | |
| 1Spring Bank Technologies, Inc., 113 Cedar Street, Milford, MA 01757, USA; 2Division of Molecular Virology and Immunology, Georgetown University, Rockville, MD, USA; 3Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA | |
| kiyer@springbanktech.comjmorrey@cc.usu.edu | |
| 67. | Characterization of Influenza Virus Clinical Isolates Obtained during Clinical Study of Arbidol |
| Irina Leneva1, Elena Burtseva2, Elena Shevchenko2, Alexander Shuster3 | |
| 1Centre of Chemistry of Drugs, Moscow, Russia; 2Ivanovsky Institute of Virology, Moscow, Russia; 3Masterlek, Moscow, Russia | |
| 68. | Preclinical Development of a New Class of Orally Active Drug Candidates for the Treatment of RSV Infections |
| Angela Luttick1, Bo Lin1, Craig Morton1, Simon Tucker1, Silas Bond1, Alistair Draffan1, John Lambert1, Chin-Yu Lim1, Jeff Mitchell1, Vanessa Sanford1, Jane Ryan1, Annette Kerr1, Jega Iswaran1, JoAnn Suzich2, Mike McCarthy2 | |
| 1Biota Holdings Limited; 2MedImmune, Inc. | |
| 69. | Carbohydrate-Binding Agents (CBAs) Potently Inhibit HIV Infection in Human Primary Monocytes/Macrophages and Efficiently Prevent Viral Capture and Subsequent Transmission to CD+4 T Lymphocytes |
| Michela Pollicita1,2, Stefano Aquaro2, Willy J. Peumans3, Els JM Van Damme3, Carlo Federico Perno2, Dominique Schols1, Jan Balzarini1 | |
| 1Rega Institute for Medical Research, K.U.Leuven, Leuven, Belgium; 2University of Rome, Tor Vergata, Italy; 3Department of Molecular Biology, Ghent University, Belgium | |
| 70. | Generation and Characterization of Fully Human Antibodies Against Orthopoxviruses |
| Tatynana Yun1, Nina Tikunova1, Ludmila Shingarova2 | |
| 1FSRI SRC VB “Vector”; 2Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry | |
| 71. | Susceptibility of German Porcine H3N2 influenza A Viruses Against Existing Antiviral Drugs |
| Katja Bauer1, Christina Schrader2, Jochen Suess3, Peter Wutzler1, Michaela Schmidtke1 | |
| 1Institute of Virology and Antiviral Therapy, FSU, Jena, Germany; 2Federal Institute for Risk Assessment, Berlin, Germany; 3Friedrich Loeffler Institute, Jena, Germany | |
| 72. | Activation of GS-7340 and Other Tenofovir Phosphonoamidate Prodrugs by Human Proteases |
| Gabriel Birkus, Nilima Kutty, Gong-Xin He, Andrew Mulato, William Lee, Martin McDermott, Tomas Cihlar | |
| Gilead Science, 333 Lakeside Drive, Foster City, CA 94404, USA | |
| 73. | NIM811, A Cyclophilin Inhibitor, and NM107, an HCV Polymerase Inhibitor, Synergistically Inhibits HCV Replication and Suppresses the Emergence of Resistance In Vitro |
| Joanna Boerner, Sue Ma, Teresa Compton, Kai Lin | |
| Novartis Institutes for Biomedical Research, 500 Technology Sq., Cambridge, MA 02139, USA | |
| 74. | Identification of Novel Low Molecular Weight HIV-1 gp41 Fusion Inhibitors Using A New Quantitative High Throughput Fluorescence Intensity Assay |
| Miriam Gochin1,2, Lifeng Cai1 | |
| 1Dept. Basic Sciences, Touro University—California, Vallejo, CA 94592, USA; 2Dept. Pharmaceutical Chemistry, UCSF, San Francisco, CA 94143, USA | |
| 75. | Development of ATP/Luminescence Assays for Profiling Compounds Against a Panel of Positive-Strand RNA Viruses |
| Edwin Gong, Tania Ivens, Christel Van den Eynde, Sabine Hallenberger, Kurt Hertogs | |
| Tibotec BVBA, Generaal De Wittelaan L11B3, 2800 Mechelen, Belgium | |
| 76. | Discovery of Two Novel Classes of Inhibitors of Hepatitis C Virus (HCV) Replication utilizing a Dicistronic Reporter HCV Replicon High Throughput Assay |
| Weidong Hao, Peter Weady, Fausto Maldonado, Amy Patick, Rohit Duggal | |
| Pfizer Global Research and Development, San Diego, CA 92121, USA | |
| 77. | Development and Validation of a High Throughput Screen for Inhibitors of Respiratory Syncytial Virus |
| Marintha Heil, Michael McDowell, Colleen Jonsson, William Severson | |
| Department of Biochemistry and Molecular Biology, 2000 9th Avenue South, Southern Research Institute, Birmingham, AL 35205, USA | |
| 78. | Development of Intergenotypic Chimeric Replicons for Broad-Spectrum Antiviral Activity Characterization of Hepatitis C Virus Polymerase Inhibitors |
| Koleen Herlihy | |
| Pfizer PGRD, La Jolla Laboratories | |
| 79. | shRNAs Targeting Hepatitis C: Effects of Sequence and Structural Features, and Comparison With siRNA |
| Brian Johnston1,4, Alexander Vlassov1,3, Brent Korba2, Heini Ilves1, Roger Kaspar1,5, Sergei Kazakov1, Kristine Farrar2, Sampa Mukerjee2, Attila Seyhan1 | |
| 1Somagenics, Inc., Santa Cruz, CA, USA; 2Department of Microbiology and Immunology, Georgetown University Medical Center; 3Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia; 4Department of Pediatrics, Stanford University School of Medicine; 5TransDerm, Inc., Santa Cruz, CA, USA | |
| 80. | Synthesis and Anti-HBV Activity of 7-Deaza-Neplanocin A Analogs |
| Hyo-Joong Kim1, Ashoke Sharon1, B. E. Korba2, Chung K. Chu1 | |
| 1The University of Georgia College of Pharmacy, Athens, GA 30602; 2Georgetown University School of Medicine, Rockville, MD 20850, USA | |
| 82. | Pharmacodynamics of NPI-5291, an Adamantane Class Compound, for Influenza A Viruses |
| James McSharry1, Kris Zager1, Qingmei Weng1, David Chernoff2, George Drusano1 | |
| 1Ordway Research Institute; 2Neuromolecular Pharma | |
| 83. | The Triple Combination of Tenofovir, Emtricitabine and Efavirenz Shows Synergistic Anti-HIV-1 Activity In Vitro |
| F. Myrick1, J. Feng1, E. Svarovskaia1, M. Miller2, K. Borroto-Esoda1 | |
| 1Gilead Sciences, Durham, NC, USA; 2Gilead Sciences, Foster City, CA, USA | |
| 84. | High Throughput Screening of a 100,000 Compound Library for Inhibitors of Influenza A virus (H3N2) |
| William Severson1, Michael McDowell1, Lynn Rasumussen2, Mindy Sosa2, Subramaniam Ananthan3, James Noah1, Lucile White2, Colleen Jonsson1 | |
| 1Department of Biochemistry and Molecular Biology; 2High Throughput Screening Center; 3Department of Chemistry, Southern Research Institute, Birmingham, AL 35205, USA | |
| 85. | Antiviral Activity of Reverse Transcriptase Inhibitors against Porcine Endogenous Retroviruses (PERV) |
| Minyi Shi1,2, Xin Wang1, Erik De Clercq3, Sonshin Takao2, Masanori Baba1 | |
| 1Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; 2Frontier Science Research Center, Kagoshima University, Kagoshima, Japan; 3Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium | |
| 86. | 17-AAG, an Hsp90 Inhibitor, Suppress Hepatitis C Virus (HCV) Replication |
| Saneyuki Ujino1, Kunitada Shimotohno3, Hiroshi Takaku1,2 | |
| 1Department of Life and Environmental Sciences; 2High Technology Research Center, Chiba Institute of Technology, 2-17-1 Tsudanuma Narashino, Chiba 275-0016, Japan; 3Department of Viral Oncology, Institute for Virus Research, Kyoto University, Kyoto 606-0507, Japan | |
| 87. | Development of Anti-Infective Topical Microbicides: 2. Quantifying Inhibition of Virus Transmission in Microbicidal Setting |
| Karen Watson, Lu Yang, Robert Buckheit Jr. | |
| ImQuest BioSciences, Inc., Frederick, MD, USA | |
| 88. | Development of Anti-Infective Topical Microbicides: 1. Effects of Seminal and Vaginal Fluids and Other Additives on Viral Infection and Drug Efficacy |
| Karen Watson, Lu Yang, Robert Buckheit Jr. | |
| ImQuest BioSciences, Inc., Frederick, MD, USA | |
| 89. | Development of Anti-Infective Topical Microbicides: 3. Combination Microbicidal Approaches Targeting Multiple Virus Targets or Utilizing Multi-Functional Anti-Infective Agents |
| Karen Watson, Tracy Hartman, Lu Yang, Robert Buckheit Jr. | |
| ImQuest BioSciences, Inc., Frederick, MD, USA | |
| 90. | Peptidomimetic Dimerization Inhibitors of HIV-1 Protease: Further Insights Into Structural Variations and Mechanism of Action |
| Ludovic Bannwarth1, Thierry Rose2, Silvia Frutos3, Ernest Giralt3, Regis Vanderesse4, Brigitte Jamart-Grégoire4, Anamaria Vidu5, Sandrine Ongeri5, Sames Sicsic5, Christophe Pannecouque6, Erik De Clercq6, Michèle Reboud-Ravaux1 | |
| 1Lab. Molecular and Functional Enzymology, FRE2852, CNRS-University Paris 6, Paris, France; 2Macromolecular Biophysics Facility, Institut Pasteur, Paris, France; 3Institut di Recerca Biochèmica, Parc scientific de Barcelona, Barcelona, Spain; 4Lab. Macromol. Chemistry and Physics, UMR7568, ENSIC, Nancy, France; 5Lab. Mol. Recognition and Synthesis, Biocis-CNRS, UMR C8076, Fac. Pharmacy, Châtenay-Malabry, France; 6Rega Institute, Leuven, Belgium | |
| 91. | A High Throughput HIV-1 Full Replication Assay that Includes HIV-1 Vif as an Antiviral Target |
| Joan Cao, Jason Isaacson, Amy Patick, Wade Blair | |
| Pfizer Global Research and Development, La Jolla, CA, USA | |
| 92. | DC-SIGN is not Required for HIV-1 Transmission to CD4+ T Lymphocytes |
| Imma Clotet-Codina, Berta Bosch, Ruth Peña, Bonaventura Clotet, Margarita Bofill, José A. Esté | |
| Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain | |
| 93. | The Virtues of Unique Ribonucleotide Reductase Inhibitors Didox and Trimidox for Retrovirus Therapy |
| Howard Elford1, Ron Lee2, Jadwiga Turchan3, Vincent Gallicchio4, Michael Ussery5, John Hiscott2, Avindra Nath3 | |
| 1Molecules for Health, Inc.; 2McGill University; 3Johns Hopkins University; 4Clemson University; 5NIAID, National Institutes of Health | |
| 94. | Human Immunodeficiency Virus Type 1 Does Not Escape From Novel Single-Stranded DNAzyme Expression-Mediated Inhibition |
| Masaak Hyafune1, Yuka Mouri1, Naoko Miyano-Kurosaki1,2, Kahoko Hashimoto1, Hiroshi Takaku1,2 | |
| 1Department of Life and Environmental Sciences; 2High Technology Research Center, Chiba Institute of Technology, Tsudanuma, Narshino, Chiba 275-0016, Japan | |
| 95. | Characterization of a New Class of Polycyclic RSV Inhibitors |
| Angela Luttick1, Bo Lin1, Craig Morton1, Simon Tucker1, Silas Bond1, Alistair Draffan1, John Lambert1, Chin-Yu Lim1, Jeff Mitchell1, Vanessa Sanford1, Mike McCarthy2, JoAnn Suzich2, Nita Patel2, Bettina Richter2 | |
| 1Biota Holdings Limited; 2MedImmune Inc. | |
| 96. | HIV Coreceptor Switch Induced by Antagonism to CCR5 |
| Gemma Moncunill, Mercedes Armand-Ugón, Bonaventura Clotet, José A. Esté | |
| Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain | |
| 97. | Induction of IL-6 and IL-8 by siRNAs Targeting HIV Correceptor CCR5 |
| Eduardo Pauls, Jordi Senserrich, Margarita Bofill, Bonaventura Clotet, Jose Esté | |
| Retrovirology Laboratory irsiCaixa | |
| 98. | Identification and Characterization of a Novel, Potent HCV Helicase Inhibitor |
| Junzhong Peng, Chunsheng Huang, Michael G. Murray, Zhuhui Huang | |
| Southern Research Institute, Frederick, MD 21701, USA | |
| 99. | Design, Synthesis and Anti-HIV Activity of Some Novel Isatin Derivatives |
| Periyasamy Selvam1, Narayanan Murugesh2, Markandavel Chandramohan3, Zeger Debyser4, Myriam Witvrouw4, Yves Engelborghs5 | |
| 1Arulmigu Kalasalingam College of Pharmacy, Anand nagar, Krishnankoil 626190, India; 2Institute of Pharmacology, Madurai Medical College, Madurai 625020; 3Bharat Ratna Kamarajar Liver Hospital and Research Centre, Madurai 625001; 4Molecular Medicine, Katholieke Universiteit Leuven and IRC KULAK, Leuven, Flanders, Belgium; 5Laboratory for Biomolecular Dynamics, Katholieke Universiteit Leuven, Leuven, Flanders, Belgium | |
| 100. | HIV-1 Resistance to the Anti-HIV Activity of a siRNA Targeting Rev |
| Jordi Senserrich, Eduardo Pauls, Bonaventura Clotet, Jose A Esté | |
| Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol | |
| 101. | Design and Cellular Kinetics of Dansyl-Labeled CADA Derivatives With Specific Anti-HIV and CD4 Receptor Down-Modulating Properties |
| Kurt Vermeire1, Andrea Lisco2, Jean-Charles Grivel2, Paul Blank2, Vincent Schram2, Noah Duffy3, Emily Scarbrough3, Kaka Dey3, Thomas Bell3, Leonid Margolis2, Dominique Schols1 | |
| 1Rega Institute for Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium; 2Laboratory of Molecular and Cellular Biophysics, National Institute of Child Health and Human Development, Bethesda, MD 20892, USA; 3Department of Chemistry, University of Nevada, Reno, NV 89557, USA | |
| 152. | Anti-HBV Nucleotide Prodrug Analogs: Synthesis, Bioreversibility, and Cytotoxicity Studies |
| Seetharamaiyer Padmanabhan, John Coughlin, Guangrong Zhang, Cassandra Kirk, Radhakrishnan Iyer | |
| Spring Bank Technologies, Inc., 113, Cedar Street, Suite S-7, Milford, MA 01757, USA | |
| Tuesday, May 1, 2007 | |
| Mini-symposium: Hepatitis C Virus: Translating Research to Medicine | |
| Celebrity Ballroom EFGH | |
| Chairs: Joseph M. Colacino, Ph.D. and Rohit Duggal, Ph.D. | |
| 08:30 | Joseph Puglisi, Ph.D. |
| Stanford University School of Medicine, Stanford, CA, USA | |
| “Translational control in HCV infection” | |
| 09:00 | Thomas Michalak, Ph.D. |
| Memorial University of Newfoundland, St. John's, Canada | |
| “Hepatitis C Virus Lymphotropism and Occult Persistence” | |
| 09:30 | Ann Kwong, Ph.D. |
| Vertex Pharmaceuticals, Cambridge, MA, USA | |
| “Risk reduction in drug discovery: Telaprevir (VX-950) Preclinical Development” | |
| 10:00 | Break |
| 10:30 | Anita Howe, Ph.D. |
| Wyeth Research, Collegeville, PA, USA | |
| “Discovering Hepatitis C Polymerase Inhibitors” | |
| 11:00 | John Tatlock, Ph.D. |
| Pfizer Global Research & Development, San Diego, CA, USA | |
| “Discovery of Dihydropyrone-containing Hepatitis C NS5B Polymerase Inhibitors with Potent Antiviral Activity” | |
| 11:30 | Dr. Tarek Hassanein, MD |
| University of California, San Diego, CA, USA | |
| “Hepatitis C: The Current Epidemic” | |
| 12:00 | General Panel Discussion |
| 12:30 | Adjourn. |
| Free afternoon and Palm Springs Tours | |
| Wednesday, May 2, 2007 | ||
| Prusoff Young Investigator Award Lecture | ||
| Celebrity Ballroom EFGH | ||
| 09:00 | Presentation of Award: Christopher McGuigan, Ph.D., President ISAR | |
| Awardee Lecture: Chris Meier, Ph.D., University of Hamburg, Hamburg, Germany | ||
| “Prodrugs of antiviral nucleotides and phosphonates—the /cyclo/Sal-story” | ||
| Oral Session III: Herpesviruses I and Poxviruses I | ||
| Celebrity Ballroom EFGH | ||
| Chairs: Mark Prichard, Ph.D. and Mark Schleiss, MD | ||
| 09:45 | 15. | Synthesis and Structure–Activity Aspects of Some Cyclic Cidofovir Peptidomimetic Prodrugs |
| Larryn W. Peterson1, Boris A. Kashemirov1, Katarzyna M. Blazewska1, Julie Breitenback4, Kathy Borysko4, John C. Drach3,4, Jae Seung Kim2, Paul Kijek2, John M. Hilfinger2, Charles E. McKenna1 | ||
| 1Dept. of Chemistry, University of Southern California, Los Angeles, CA 90089, USA; 2TSRL, Inc., Ann Arbor, MI 48108 USA; 3College of Pharmacy, University of Michigan, Ann Arbor, MI 48109 USA; 4School of Dentistry, University of Michigan, Ann Arbor, MI 49109, USA | ||
| 10:00 | 16. | Synthesis and Antiviral Activity of 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine and its Ester Prodrugs |
| Marcela Krecmerova1, Antonin Holy1, Alois Piskala1, Graciela Andrei2, Robert Snoeck2, Lieve Naesens2, Johan Neyts2, Jan Balzarini2, Erik De Clercq2 | ||
| 1Gilead Sciences & IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic; 2Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium | ||
| 10:15 | 17. | In Vivo Antiviral Activity of 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine and its Cyclic Form |
| Graciela Andrei1, Marcela Krecmerová2, Antonín Holý2, Lieve Naesens1, Johan Neyts1, Jan Balzarini1, Erik De Clercq1, Robert Snoeck1 | ||
| 1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium; 2Gilead Sciences & IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nam. 2, 166 10 Prague 6, Czech Republic | ||
| 10:30 | Break | |
| 10:50 | Invitation to the 21st ICAR, Montreal, Quebec, John A. Secrist, III | |
| 11:00 | ISAR Business Meeting | |
| 11:15 | 18. | Isolation and Characterization of an Helicase-Primase Inhibitor (HPI)-Resistant HSV-1 Mutant in Tissue Culture and a Mouse-Skin Model |
| Subhajit Biswas, Hugh Field | ||
| Cambridge University Centre for Veterinary Science | ||
| 11:30 | 19. | Evidence For In Vivo Inhibition of CMV Infection by the Quinazoline Class Protein Kinase Inhibitor Gefitinib |
| Mark Schleiss1, Michael McVoy2, Xiaohong Cui2, Yeon Choi1, Jodi Anderson1, Thomas Stamminger3, Bert Klebl4, Jan Eickhoff4, Manfred Marschall3 | ||
| 1Center for Infectious Diseases and Microbiology Translational Research, Department of Pediatrics, Minneapolis, MN, USA; 2Virginia Commonwealth University, Department of Pediatrics, Richmond, VA, USA; 3Institute for Clinical and Molecular Virology, University of Erlangen-Nuremberg, Germany; 4GPC Biotech AG, Martinsried, Germany | ||
| 11:45 | 20. | Successful Treatment in the Monkeypox and Variola Primate Models of Smallpox by the Oral Drug ST-246 |
| John Huggins1, Arthur Goff1, Mucker Eric1, Nancy Twenhafel1, Jennifer Chapman1, Mallory Tate2, Rob Jordan3, Tove’ Bolken3, Dennis Hruby3 | ||
| 1US Army Medical Research Institute of Infectious Diseases; 2Centers for Disease Control and Prevention; 3Siga Technologies Inc. | ||
| 12:00 | Lunch | |
| Oral Session IV: Hepatitis Viruses I | ||
| Celebrity Ballroom EFGH | ||
| Chairs: Michael Murray, Ph.D. and Ann Kwong, Ph.D. | ||
| 14:00 | 21. | Design and Characterization of R1626, A Prodrug of the HCV Replication Inhibitor R1479 (4′-Azidocytidine) With Enhanced Oral Bioavailability |
| Klaus Klumpp1, David Smith1, Michael Brandl1, Tom Alfredson1, Keshab Sarma1, Mark Smith1, Isabel Najera1, Wen-Rong Jiang1, Sophie Le Pogam1, Vincent Leveque1, Han Ma1, Yaping Tu1, Rebecca Chan1, Chiao-Wen Chen1, Xiaoyang Wu1, Raj Birudaraj1, Steven Swallow1, Joseph A. Martin1, Nick Cammack1, Heather Berns1, Scott Fettner2, David Ipe1, Marie Mannino2, Edward O’Mara2, Carla Washington1, Stuart Roberts3, Graham Cooksley4, Greg Dore5, David Shaw6 David R Blue Jr1, Friederike Zahm7, George Hill1 | ||
| 1Roche Palo Alto LLC; 2F. Hoffmann-La Roche Ltd, Nutley, NJ, USA; 3Alfred Hospital, Melbourne, Vic., Australia; 4Royal Brisbane Hospital, Brisbane, Qld., Australia; 5Christchurch Clinical Study Trust, Christchurch, New Zealand; 6Royal Adelaide Hospital, Adelaide, SA, Australia; 7F. Hoffmann La Roche, Basel, Switzerland | ||
| 14:15 | 22. | Novel 4′-Azido-2′-Deoxy-Nucleoside Analogs Are Potent Inhibitors of NS5B-Dependent HCV Replication |
| David Smith1, Han Ma1, Sophie Le Pogam1, Vincent Leveque1, Carl Brown1, Nils Gunnar Johansson2, Genadiy Kalayanov2, Staffan Eriksson3, Elena Usova3, Christian Sund2, Anna Winqist2, Tatiana Maltseva2, Mark Smith1, Joseph Martin1, Isabel Najera1, Klaus Klumpp1 | ||
| 1Roche Palo Alto LLC; 2Medivir AB, Huddinge, Sweden; 3Swedish University of Agricultural Sciences, Dept. Mol. Biosciences, The Biomedical Centre, Uppsala, Sweden | ||
| 14:30 | 23. | Characterization of the Intracellular Metabolism of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyl-Cytidine and the Inhibition of HCV Polymerase NS5B by its 5′-Triphosphate Species |
| Han Ma, Wen-Rong Jiang, Nicole Robledo, Vincent Leveque, Samir Ali, David Smith, Mohammad Masjedizadeh, Teresa Lara-Jaime, Nick Cammack, Klaus Klumpp, Julian Symons | ||
| Roche Palo Alto LLC, Palo Alto, CA, USA | ||
| 14:45 | 24. | Sub Micromolar Inhibitors of HCV Generated from Inactive Nucleosides by Application of ProTide Technology |
| Christopher McGuigan1, Plinio Perrone1, Giovanna Luoni1, Mary Rose Kelleher1, Felice Daverio1, Annette Angell1, Sinead Mulready1, Costantino Congiatu1, Sonal Rajyaguru2, Joseph Martin2, Vincent Lévêque2, Sophie Le Pogam2, Isabel Najera2, Klaus Klumpp2, David Smith2 | ||
| 1Welsh School of Pharmacy, Cardiff University; 2Roche Palo Alto | ||
| 15:00 | 25. | GL59728: A Potent Allosteric Inhibitor of the HCV NS5b RNA Dependent RNA Polymerase With Excellent Pharmacokinetic Properties |
| Christopher Roberts, Janos Botyanszki, Dong-fang Shi, Joshua Gralapp, Samantha Koo-McCoy, John Zhang, Kevin Fung, Mohan Sivaraja, Jeffrey Pouliot, Ting Wang, Kevin Dunlop, Wenbao Li, Lillian Lou, Uli Schmitz, Peter Young, Ron Griffith | ||
| Genelabs Technologies, Inc. 505 Penobscot Dr., Redwood City, CA 94063, USA | ||
| 15:15 | 26. | Substituted Imidazopyridines As Potent Inhibitors of Hepatitis C Virus Replication that Target the Viral Polymerase |
| Inge Vliegen1, Jan Paeshuyse1, Laura S. Lehman2, Weidong Zhong2, Sofie Roofthooft1, Hélène Dutartre3, Barbara Selisko3, Bruno Canard3, Nina Boddeker2, Steven Bondy2, David Oare2, Erik De Clercq1, William A. Lee2, Gerhard Pürstinger4, Johan Neyts1 | ||
| 1Rega Institute, K.U.Leuven, Belgium; 2Gilead Sciences, Foster City, CA, USA; 3CNRS and Universités d’Aix-Marseille I et II, France; 4Universität Innsbruck, Austria | ||
| 15:30 | 27. | Potent HCV NS5B Polymerase Inhibitors Derived From 5-Hydroxy-3(2H)-Pyridazinones: Part 1. Exploration of Pyridazinone 4-Substituent Variation |
| Y. Zhou, L.-S. Li, S. Webber, P. Dragovich, D. Murphy, C. Tran, F. Ruebsam, A. Shah, M. Tsan, R. Showalter, J. Brooks, E. Okamoto, T. Nolan, D.A. Norris, L. Kirkovsky | ||
| Anadys Pharmaceuticals, Inc., San Diego, CA, USA | ||
| 15:45 | 28. | Development of Hepatitis C Virus (HCV) Chimeric Replicons for Identifying Broad Spectrum NS3 Protease Inhibitors |
| Joseph Binder, Selwyna Tetangco, Megan Wick, Karen Maegley, Laura Lingardo, Amy Patick, George Smith | ||
| Pfizer Global Research and Development (La Jolla, CA, USA) | ||
| Poster Session II: Herpesviruses, Poxviruses, other Antivirals and Medicinal Chemistry | |
| Celebrity Ballroom ABCD | |
| 16:00–18:00 | |
| 102. | An Animal Model of HCMV Infection in SCID Mice |
| Fernando Bravo, Rhonda Cardin, David Bernstein | |
| Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA | |
| 103. | Use of CpG DNA in Co-Administration With Cidofovir or Monoclonal Antibody as a Post Exposure Antiviral Therapy |
| Amanda Phelps1, Lin Eastaugh1, Art Kreig2, Amanda Gates1 | |
| 1Dstl, Biomedical Sciences, Porton Down, Salisbury, WILTS, SP4 0JQ; 2Coley Pharmaceutical Group Ltd. | |
| 104. | Efficacy of Oral CMX-001 Therapy Against Human Herpes Virus-6 Infections in SCID-hu Mice |
| Debra Quenelle1, Mark Prichard1, Shannon Daily1, Deborah Collins1, Terri Rice1, George Painter2, Alice Robertson2, Earl Kern1 | |
| 1Department of Pediatrics, University of Alabama School of Medicine; 2Chimerix, Inc. | |
| 105. | Efficacy of Delayed Therapy Using Combinations of ST-246 with CMX-001 Against Systemic Cowpox Virus Infections in Mice |
| Debra Quenelle1, Mark Prichard1, Kathy Keith1, Deborah Collins1, Robert Jordan2, Dennis Hruby2, George Painter3, Alice Robertson3, Earl Kern1 | |
| 1Department of Pediatrics, University of Alabama School of Medicine; 2Siga Technologies, Inc.; 3Chimerix, Inc. | |
| 106. | Design and Synthesis of Novel anti-HCMV Agents: Modifications to the Bicyclic Pyrimidine Base |
| Rina Adak1, Christopher McGuigan1, Robert Snoeck2, Graciella Andrei2, Eric De Clercq2, Jan Balzarini2 | |
| 1Welsh School of Pharmacy, Cardiff University, Cardiff, UK; 2Rega Institute for Medical Research, Leuven, Belgium | |
| 107. | HINT as Putative Phosphoramidase Responsible of ProTides Activation: Molecular Modelling Studies |
| Costantino Congiatu, Christopher McGuigan, Andrea Brancale | |
| The Welsh School of Pharmacy, Cardiff University, Cardiff, UK | |
| 108. | Design, Synthesis, and Biological Evaluation of Novel Anti-VZV Agents |
| Marco Derudas1, Christopher McGuigan1, Robert Snoeck2, Graciella Andrei2, Erik De Clercq2, Jan Balzarini2 | |
| 1Welsh School of Pharmacy, Cardiff University, Cardiff, UK; 2Rega Institute for Medical Research, Leuven, Belgium | |
| 109. | Synthesis and Properties of Chiral Open-Ring Acyclic Nucleoside Bisphosphonates |
| Petra Doláková, Martin Dračínský, Antonín Holý | |
| Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nam. 2, 166 10 Prague | |
| 110. | Properties of Aminoacid Esters Linked to cyclo Sal-Pronucleotides |
| Henning Jessen1, Jan Balzarini2, Chris Meier1 | |
| 1University of Hamburg, Institute of Organic Chemistry, Hamburg, Germany; 2Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium | |
| 111. | Discovery of Cage Antiviral Agents |
| Yuri Klimochkin1, Eugene Boreko2, Andrey Shiryaev1, Igor Moiseev1, Eugene Golovin1, Marina Leonova1 | |
| 1Samara State Technical University, 244 Molodogvardeyskaya St., 443100 Samara, Russia; 2Research Institute for Epidemiology & Microbiology, 23 Philimonova St., 220114 Minsk, Belarus | |
| 112. | Pyrimidine Nucleosides Containing 5-Substituent: Synthesis and Antiviral Activity |
| Stanislav V. Korkach, Olga A. Valueva, Veronika V. Doubniakova, Vladimir A. Korshun, Alexey V. Ustinov | |
| Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia | |
| 113. | New Ribonucleosides with Surrogate Bases: Synthesis, Enzymology, Molecular Docking Studies and Antiviral Activity |
| Vasu Nair1, Xiaohui Ma1, Fan Zhang1, Malik Nishonov1, Qingning Shu1, Robert Sidwell2, Earl Kern3 | |
| 1Center for Drug Discovery and Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA; 2Institute of Antiviral Research, Utah State University, Logan, UT 84322, USA; 3University of Alabama at Birmingham, Birmingham, AL 35233, USA | |
| 114. | Novel Synthetic Approaches to Cidofovir and Foscarnet Prodrugs |
| Larryn W. Peterson1, Boris A. Kashemirov1, Kanokkarn Saejueng1, Julie Breitenbach4, Kathy Borysko4, John C. Drach3,4, Jae Seung Kim2, Paul Kijek2, Stefanie Mitchell2, John M. Hilfinger2, Charles E. McKenna1 | |
| 1Dept. of Chemistry, University of Southern California, Los Angeles, CA 90089, USA; 2TSRL, Inc., Ann Arbor, MI 48108, USA; 3College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA; 4School of Dentistry, University of Michigan, Ann Arbor, MI 49109, USA | |
| 115. | Chloroquine a Novel and Versatile Anti viral Agent with nine prong modes of anti viral actions and postive approach in radical cure of viral hepatitis varieties B and C Both Acute and Chronic Forms |
| M. Chandramohan1, S.C Vivekanandan1, D. Sivakumar1, P. Selvam2 | |
| 1Kamarajar Jaundice Liver Hospital & Research Centre, Madurai 625001,Tamilnadu, India; 2Arulmigu Kalasalingam College of Pharmacy, Krishnankoil, India | |
| 116. | Brivudin (ZostexR) in the Treatment of Herpes Zoster in Immunosuppressed Patients |
| Astrid Meerbach1, Peter Wutzler1, Bernd Gruhn2 | |
| 1Institute of Virology and Antiviral Therapy, Friedrich-Schiller University Jena; 2Department of Pediatrics, Friedrich-Schiller University Jena | |
| 117. | Proteflasid as Inhibitor of EBV-Infection |
| N. Nesterova1, S. Zagorodnya1, G. Baranova1, A. Golovan1, V. Atamaniuk2, A. Novik2 | |
| 1Institute of Microbiology and Virology, Ukrainian NAS, Kyiv, Ukraine; 2Ecopharm Research and Production Company, Kyiv, Ukraine | |
| 118. | Enhanced Antiviral Actitity of Hexadecyloxypropyl-PME-N6-cyclopropyl-diaminopurine Against Herpesviruses, Hepatitis B Virus and Vaccinia Virus, In Vitro |
| Graciela Andrei1, Robert Snoeck1, Johan Neyts1, Erik De Clercq1, Nadejda Valiaeva2, James Beadle2, Karl Hostetler2 | |
| 1Rega Institute for Medical Research, Leuven, Belgium; 2University of California, San Diego and the San Diego Veterans Medical Research Foundation, San Diego, CA, USA | |
| 119. | Molecular Design of Active Antiherpetic Compounds Using Hierarchic QSAR Technology |
| A. Artemenko1, V. Kuz’min1,3, E. Muratov1,3, A. Fedchuk2, V. Lozitsky2, T. Gridina2, R. Lozytska1, S. Basok1, D. Chikhichin1 | |
| 1A.V.Bogatsky Physico-Chemical Institute NAS of Ukraine, 86 Lustdorfskaya doroga, Odessa, Ukraine; 2Ukrainian I.I.Mechnikov Research Anti-Plague Institute, Odessa, Ukraine; 3Jackson State University, Jackson, MS, USA | |
| 120. | Anti-orthopoxviral Activity of the 2-Cycloalkylimino-5-(4-Nitrophenyl)-1,3,4-Thiadiazines |
| Evgeny Belanov1, Larisa Sidorova2, Vladimir Rusinov2, Nikolay Bormotov1, Sergey Balakhnin1, Olga Serova1, Valerii Charushin2, Oleg Chupakhin2 | |
| 1State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Novosibirsk reg., Russia; 2Ural State Technical University, Yekaterinburg, Russia | |
| 121. | Development of Novel Cell Lines for the Detection and Quantification of Herpesvirus Replication |
| Susan Binford, Amy Patick, George Smith | |
| Pfizer Global Research and Development, La Jolla, CA, USA | |
| 122. | Discovery of Novel Small Molecule Inhibitors of Dengue Virus Replication |
| Chelsea Byrd, Eric Stavale, Andrews Wieczorek, Thaun Tran, Dennis Hruby, Robert Jordan | |
| SIGA Technologies, Corvallis, OR, USA | |
| 123. | Antiviral Activities of New Cidofovir Analogs Against Camelpox Virus, Used As A Model of Variola Virus, in Human Skin Equivalent Cultures |
| Sophie Duraffour1,2, Robert Snoeck1, Joost Van Den Oord3, Marcela Krecmerová4, Antonín Holý4, Jean-Marc Crance2, Daniel Garin2, Erik De Clercq1, Graciela Andrei1 | |
| 1Rega Institute for Medical Research, K.U. Leuven, Belgium; 2CRSSA, Grenoble, France; 3Pathology Dpt, K.U. Leuven, Belgium; 4Gilead Sciences & IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic | |
| 124. | Cytopathic Maporal Hantavirus Infection of Vero E6 Cells |
| Brian Gowen1, Kie-Hoon Jung1, Michelle Mendenhall1, Irina Gavrilovskaya2, Siddharthan Venkatraman1, Erich Mackow2,3, Robert Sidwell1 | |
| 1Institute for Antiviral Research, Utah State University; 2The Department of Medicine and the Department of Molecular Genetics and Microbiology, State University of New York at Stony Brook; 3Northport Veterans Administration Medical Center | |
| 125. | Comparison of Anti-Proliferative Activity of Selected Antiviral Agents in Various Assay Systems |
| Caroll Hartline, Harden Emma, Earl Kern, Prichard Mark | |
| Department of Pediatrics, University of Alabama School of Medicine | |
| 126. | Synthesis and Structure Activity Relationships among Non-nucleoside Analogs of Toyocamycin Active against Herpesviruses |
| Jack M. Hinkley1, Katherine Z. Borysko2, Julie M. Breitenbach2, Keenan Bora1, Shigetada Kosai1, John C. Drach1,2, Leroy B. Townsend1 | |
| 1Department of Medicinal Chemistry, College of Pharmacy; 2Department of Biologic & Materials Sciences, School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA | |
| 127. | Combinations of CMX-001 and ST-246 Synergistically Inhibit Orthopoxvirus Replication In Vitro |
| Kathy Keith1, Earl Kern1, Shalisa Sanders1, Robin Conley1, Robert Jordan2, Dennis Hruby2, George Painter3, Mark Prichard1 | |
| 1University of Alabama School of Medicine, Dept. of Pediatrics, Birmingham AL, USA; 2SIGA Technologies, Inc., Corvallis, OR, USA; 3Chimerix Inc., Research Triangle Park, NC, USA | |
| 128. | Inhibition of Cellular Entry and Spread of Lymphocytic Choriomeningitis Virus by Amphipathic DNA Polymers |
| Andrew Lee1, Jillian Rojek1, Anette Gundersen1, Jean-Marc Juteau2, Michael Oldstone1,3, Andrew Vaillant2, Stefan Kunz1 | |
| 1Molecular and Integrative Neurosciences Department (MIND), Scripps Research Institute; 2REPLICor Inc. Laval, Quebec, Canada; 3Department of Infectology, Scripps Research Institute | |
| 129. | Benzimidazole with Broad Spectrum of Antiviral Action |
| Regina Lozytska1, Dmitry Chikhichin1, Victror Lozitsky1,3, Alla Fedchuk2, Victor Kuz’min1, Anatoly Artemenko1, Larisa Shitikova2, Lubov’ Mudrik2, Tatjana Gridina2, Eugene Muratov1,3 | |
| 1A.V. Bogatsky Phys.-Chem. Institute, NAS of Ukraine; 2Ukrainian I.I.Mechnikov Research Anti-Plague Institute, Odessa, Ukraine; 3Jackson State University, Jackson, MS, USA | |
| 130. | A Rapid DNA Hybridization Assay for the Evaluation of Antiviral Compounds Against Epstein-Barr Virus |
| Mark Prichard, Shannon Daily, Geraldine Jefferson, Amie Perry, Earl Kern | |
| Department of Pediatrics, University of Alabama School of Medicine | |
| 131. | Design, Synthesis, Antiviral Activity and Cytotoxicity of Novel Sulphonamide Derivatives |
| P. Selvam1, D.F. Smee2, B.B. Gowen2, C.W. Day2, D.L. Barnard2, J.D. Morrey2 | |
| 1Arulmigu Kalasalingam College of Pharmacy, Krishnankoil, India; 2Institute for Antiviral Research, Utah State University, Logan, UT, USA | |
| 132. | Inhibition of the Tax-Dependent Human T-Lymphotropic Virus Type 1 (HTLV-1) Replication in Persistently Infected Cells by the Naphthalene Derivative JTK-101 |
| Xin Wang1, Minyi Shi1, Jun-ichi Fujisawa3, Yuetsu Tanaka4, Shuji Izumo2, Satoru Ikeda5, Masanori Baba1 | |
| 1Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; 2Division of Molecular Pathology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; 3Department of Microbiology, Kansai Medical University, Moriguchi, Japan; 4Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan; 5Japan Tobacco Inc., Osaka, Japan | |
| 133. | Combinations of Thiovir and Neuraminidase Inhibitors Exert Synergistic Antiviral Activity on Human, Equine and Avian Influenza In Vitro |
| Shani Waninger, Silvestre Ramos, Joan Robbins | |
| ADVENTRX Pharmaceuticals, San Diego, CA 92121, USA | |
| 135. | Development of a Cell-Based Assay For Identification of Viral Entry Inhibitors Against SARS-CoV by High Throughput Screening (HTS) |
| Chengsheng Zhang1, Yan Feng1, Gillian Wong1, Liping Wang2, Jonathan Cechetto3, Jan Blanchard3, Eric Brown3, James Mahony1 | |
| 1Department of Pathology & Molecular Medicine, McMaster University, Canada; 2Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA; 3Department of Biochemistry and High Throughput Screening Laboratory, McMaster University, Canada | |
| 136. | The Inhibitory Effects of Medicinal Herbs on SARS-CoV Entry In Vitro |
| Min Zhuang1, Hong Jiang2, Peng Xiao1, Yasuhiro Suzuki1, Toshio Hattori1 | |
| 1Division of Infectious and Respiratory Diseases, Department of Internal Medicine, Tohoku University, Japan; 2Institute of Laboratory Animal Science, Chinese Academy of Medical Science, Beijing, China | |
| 137. | Uptake and Metabolism of Cidofovir and Oleyloxyethyl-cidofovir in Human Papillomavirus Positive ME-180 Human Cervical Cancer Cells |
| Kathy A. Aldern, James R. Beadle, Julissa Trahan, Karl Y. Hostetler | |
| University of California, San Diego, La Jolla, California and the Veterans Medical Research Foundation, San Diego, CA, USA | |
| 139. | Selection of Human Cytomegalovirus Resistant to a Second Generation Methylenecyclopropane Purine |
| Katherine Z. Borysko1, Julie M. Breitenbach1, Brian G. Gentry1, Jiri Zemlicka2, John C. Drach1 | |
| 1Department of Biologic & Materials Sciences, University of Michigan, Ann Arbor, MI 48109, USA; 2Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA | |
| 140. | The Combination of Anti-Poxvirus Compounds ST-246 and TTP-018 are synergistic In Vitro |
| Yali Chen1, Chris Harver1, Guang Yang1, Dennis Hruby1, Robert Andrews2, Robert Jordan1 | |
| 1SIGA Technologies, Corvallis, OR, USA; 2TransTech Pharaceuticals, High Point, NC, USA | |
| 141. | Thiazolobenzimidazoles, a Novel Class of Enterovirus Inhibitors, Target the 2C Protein |
| Armando M. De Palma1, Ward Heggermont1, Erik De Clercq1, Alba Chimirri2, Johan Neyts1 | |
| 1Rega Institute for Medical Research, University of Leuven, Leuven, Belgium; 2Dipartimento Farmaco-Chimico, Università di Messina, Messina, Italy | |
| 142. | Selective Phosphorylation of Antiviral Drugs by Vaccinia Virus Thymidine Kinase |
| Emma Harden1, Kathy Keith1, Mary Johnson1, Alexis McBrayer1, Ming Luo2, Shihong Qiu2, Debasish Chattopadhyay2, Xuesen Fan3, Paul Torrence3, Earl Kern1, Mark Prichard1 | |
| 1Department of Pediatrics, University of Alabama School of Medicine; 2Department of Microbiology, University of Alabama School of Medicine; 3Northern Arizona University | |
| 143. | Intracellular Localization of Herpes Simplex Virus Type 1 Thymidine Kinase in Cells Infected With various Thymidine Kinase-Deficient Viruses |
| Chong-Kyo Lee, Ju Ryung Nam, Pan Kee Bae, Jee Hyun Kim, Hae Soo kim, Myung-Jin Lee | |
| Pharmacology Research Center, Korea Research Institue of Chemical Technology | |
| 144. | Substrate Specificity and Molecular Modelling of Feline Herpesvirus-1 Thymidine Kinase |
| Islam Mohammad1, Ricardo Nunez2, Laurence Tiley1, Hugh Field1 | |
| 1Centre of Veterinary Science, Uiniversity of Cambridge, UK; 2Department of Biochemistry, University of Cambridge, UK | |
| 145. | Chemical Stability and Intracellular Metabolism of 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine |
| Lieve Naesens1, Graciela Andrei1, Ivan Votruba2, Marcela Krecmerová2, Antonín Holý2, Jan Balzarini1, Erik De Clercq1, Robert Snoeck1 | |
| 1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium; 2Gilead Sciences & IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nam. 2, 166 10 Prague 6, Czech Republic | |
| 146. | Influence of Substitutes in the Central Phenyl Ring of Capsid Function Inhibitors on Anti-Coxsackievirus B3 Stivity |
| Michaela Schmidtke1, Olga Riabova2, Vadim Makarov2, Peter Wutzler1 | |
| 1Inst. of Virology and Antiviral Therapy, FSU, Jena, Germany; 2Research Center of Antibiotics, Moscow, Russia | |
| 147. | Efficacy of 5-halogenated 2’-deoxyuridines on vaccinia virus thymidine kinase positive and negative strains, and influence of cell type on antiviral potency |
| Donald Smee, Daniel Humphreys, Brett Hurst, Robert Sidwell | |
| Institute for Antiviral Research, Utah State University, Logan, UT, USA | |
| 148. | Nucleosidic Fusion Inhibitors |
| M. St.Vincent1, S. Korkach2, O. Valueva2, V. Korshun2, A. Ustinov2, L. Schang1 | |
| 1Biochemistry, University of Alberta, Canada; 2Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Russia | |
| 149. | Enhanced Potency and Efficacy of 29-mer shRNAs in Inhibition of enterovirus 71 |
| Eng-Lee Tan1, May-Chin Tan2, Vincent Tak- Kwong Chow1, Chit-Laa Poh1 | |
| 1Department of Microbiology, National University of Singapore, Singapore; 2Department of Biochemistry, National University of Singapore, Singapore | |
| 150. | Crosstalk Between Scavenger Receptors (SR-A) and Toll-like Receptors (TLR) Results in Rapid Pro-Inflammatory Cytokine Differentiation in Monocytes Exposed to Cytomegalovirus (CMV) |
| Hooi Yew1, Christopher Harrison1,2 | |
| 1Children's Mercy Hospital; 2University of Missouri School of Medicine-Kansas City | |
| 151. | Solid-phase synthesis of the anti-HBV dinucleotide SB 9000—Microwave-assisted Functionalization of Solid Supports |
| Seetharamaiyer Padmanabhan, John Coughlin, Radhakrishnan Iyer | |
| Spring Bank Technologies, Inc., 113, Cedar Street, Milford, MA 01757, USA | |
| Thursday, May 3, 2007 | ||
| Oral Session V: Hepatitis Viruses II, Herpesviruses II and Poxviruses II | ||
| Celebrity Ballroom EFGH | ||
| Chairs: Tomas Cihlar, Ph.D. and Rick Wagner, Ph.D. | ||
| 08:30 | Plenary Speaker | |
| Christopher Aiken, Ph.D., Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA | ||
| “Small Molecule Inhibition of HIV-1 Maturation” | ||
| 09:00 | 29. | The Cyclophilin Inhibitor Debio-025 is A Potent Inhibitor of Hepatitis C Virus Replication In Vitro With a Unique Resistance Profile |
| Lotte Coelmont1, Jan Paeshuyse1, Suzanne Kaptein1, Inge Vliegen1, Artur Kaul2, Erik De Clercq1, Brigitte Rosenwirth4, Pietro Scalfaro3, Raf Crabbé3, Ralf Bartenschlager2, Jean-Maurice Dumont3, Johan Neyts1 | ||
| 1Rega Institute, KULeuven, Belgium; 2University of Heidelberg, Germany; 3Debiopharm, Lausanne, Switzerland; 4Med Universitaet Wien, Austria | ||
| 09:15 | 30. | The Imidazopyrrolopyridine Analogue AG110 is A Novel, Highly Selective Inhibitor of Pestivirus Replication and Targets the Viral RNA-Dependent RNA Polymerase |
| Jan Paeshuyse1, Jean-Michel Chezal6, Matheus Froeyen1, Pieter Leyssen1, Hélène Dutartre3, Robert Vrancken2, Bruno Canard3, Carine Letellier2, Tong Li1, Harald Mittendorfer5, Frank Koenen2, Pierre Kerkhofs2, Erik De Clercq1, Piet Herdewijn1, Gerhard Puerstinger5, Alain Gueiffier4, Olivier Chavignon6, Jean-Claude Teulade6 and Johan Neyts1 | ||
| 1K.U.Leuven, Belgium; 2VAR/CODA, Belgium; 3AFMB-UMR 6098, France; 4University of Tours, France; 5University of Innsbruck, Austria; 6University of Auvergne, France | ||
| 09:30 | 31. | Nitazoxanide is an Effective Antiviral Agent Against Both HBV and HCV Replication In Vitro |
| Brent Korba1, Muller Abigail1, Ayers Marc2, Jean-François Rossignol2 | ||
| 1Dept. of Microbiology & Immunology, Georgetown Univ. Med. Ctr., Rockville, MD, USA; 2The Romark Institute for Medical Research, Tampa, FL, USA | ||
| 09:45 | 32. | Efficacy of Cationic Lipid-DNA Complexes (CLDC) on Hepatitis B Virus in Transgenic Mice |
| John D. Morrey1, Neil E. Motter1, Brandon Taro1, Fairman Jeffery2 | ||
| 1Institute for Antiviral Research, ADVS Depart., Utah State University, Logan, UT, USA; 2Juvaris BioTherapeutics, Inc., Pleasanton, CA, USA | ||
| 10:00 | Break | |
| 10:30 | 33. | Mononuclear Cells as a Transfer Vehicle for Herpes Simplex Virus (HSV) or Vaccinia Virus (VV) Infection of Epithelial Cells Grown in 3D |
| Graciela Andrei1, Joost Van den Oord2, Erik De Clercq1, Robert Snoeck1 | ||
| 1Rega Institute for Medical Research, K.U.Leuven, B-3000 Leuven, Belgium; 2Laboratory of Morphology and Molecular Pathology, K.U. Leuven, B-3000 Leuven, Belgium | ||
| 10:45 | 34. | Structural Basis for the Expanded Substrate Specificity of Vaccinia Virus Thymidine Kinase: Insight from the Crystal Structure |
| Mark Prichard1, Kathy Keith1, Mary Johnson1, Norbert Schormann2, Alexandra Samal2, Debasish Chattopadhyay2,3, Earl Kern1 | ||
| 1Department of Pediatrics, University of Alabama School of Medicine; 2Center for Biophysical Sciences & Engineering, University of Alabama School of Medicine; 3Department of Medicine, University of Alabama School of Medicine | ||
| 11:00 | 35. | Inhibition of an Innate Antiviral Response by Human Cytomegalovirus UL97 Kinase is Antagonized by Maribavir |
| Mark Prichard, Shannon Daily, Amie Perry, Caroll Hartline, Earl Kern | ||
| Department of Pediatrics, University of Alabama School of Medicine | ||
| 11:15 | 36. | Vaccination as an Antiviral Strategy for Control of Cytomegalovirus (CMV) Disease: A Vectored Vaccine Approach Targeting the UL83 (pp65) Homolog Protects Against Congenital CMV Disease in the Guinea Pig Model |
| Mark Schleiss1, Juan Lacayo1, Yasmine Belkaid2, Alistair McGregor1, Greg Stroup3, Jon Rayner4, Kim Alterson4, Jeff Chulay4, Jonathan Smith4 | ||
| 1Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, Department of Pediatrics, Minneapolis, MN, USA; 2Mucosal Immunology Unit, NIAID, National Institutes of Health, Bethesda, MD, USA; 3Meridian Biosciences, Cincinnati, OH, USA; 4AlphaVax, Research Triangle Park, NC, USA | ||
| 11:30 | 37. | JuvImmune is a Novel Vaccine Adjuvant that Enhances Protection of Mice from Lethal HSV-2 Infection Following Immunization |
| Jane Strasser1, Rhonda Cardin1, Claudia Chalk1, James Ireland1, Jeff Fairman2, David Bernstein1 | ||
| 1Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; 2Juvaris BioTherapeutics, Inc., Pleasanton, CA, USA | ||
| 11:45 | 81. | A Novel Class of Amphipathic DNA Polymers Inhibits Hepatitis C Virus Infection by Blocking Viral Entry |
| Takuya Matsumura1, Takanobu Kato1, Zonghi Hu1, Jean-Marc Juteau2, Andrew Vaillant2, Jake Liang1 | ||
| 1Liver Diseases Branch, NIDDK, NIH, Bethesda, MD, USA; 2REPLICor Inc. Laval, Quebec, Canada | ||
| 12:00 | Lunch | |
| Oral Session VI: Other Viruses and Late Breaker Presentations | ||
| Celebrity Ballroom EFGH | ||
| Chairs: Brian Gowen, Ph.D. and Roger Ptak | ||
| 13:30 | 38. | Comparative Activity of Anti-Enteroviral Agents Against Poliovirus Replication In Vitro; Implications for the End Phase of the Polio Eradication Initiative |
| Armando M De Palma1, Gerhard Pürstinger2, Amy Patick3, Koen Andries4, Erik De Clercq1, Bart Rombaut5, Johan Neyts1 | ||
| 1Rega Institute for Medical Research, University of Leuven, Leuven, Belgium; 2Department of Pharmaceutical Chemistry, Institute of Pharmacy, University of Innsbruck, Austria; 3Department of Virology, Pfizer Global Research and Development, San Diego, CA, USA; 4Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; 5Department of Pharmaceutical Biotechnology and Molecular Biology, Vrije Universiteit Brussel, Belgium | ||
| 13:45 | 39. | Carbohydrate-Binding Agents (CBAs) Selectively Target the Glycoproteins of the HCV and HIV Envelope to Prevent Viral Entry |
| J. Balzarini1, C. Bertaux2, D. Daelemans1, M. Meertens2, E.G. Cornier2, J.F. Reinus3, W.J. Peumans4, E.J.M. Van Damme4, Y. Igarashi5, T. Oki6, D. Schols1, T. Dragic2 | ||
| 1Rega Institute for Medical Research, Leuven, Belgium; 2Albert Einstein College of Medicine, Bronx, NY; 3Montefiore Medical Center, Bronx, NY; 4UGent, Gent, Belgium; 5Toyama Prefectural University, Toyama, Japan; 6Keck School of Medicine, Los Angeles, CA, USA | ||
| 14:00 | 40. | In Vitro and In Vivo Activity of T-705 Against Arenavirus and Bunyavirus Infections |
| Kie-Hoon Jung1, Min-Hui Wong1, Yousuke Furuta2, Andrew Sanders1, Michelle Mendenhall1, Kevin Bailey1, Robert Sidwell1, Brian Gowen1 | ||
| 1Institute for Antiviral Research, Utah State University, Logan, Utah; 2Toyoma Chemical Co., Ltd., 3-2-5 Nishishinjuku, Shinjuku-ku, Tokyo | ||
| 14:15 | 41. | QSAR Studies on [(Biphenyloxy)Propyl]Isoxazole Derivatives With Anti-Rhinovirus 2 Activity |
| E. Muratov1,2, V. Kuz’min1,2, A. Artemenko2, I. Volineckaya2, V. Makarov3, O. Riabova3, P. Wutzler4, M. Schmidtke4 | ||
| 1Jackson State University, Jackson, MS, USA; 2A.V. Bogatsky Physical-Chemical Institute NAS of Ukraine, Odessa, Ukraine; 3Research Center for Antibiotics, Moscow, Russia; 4Institute of Virology and Antiviral Therapy, Friedrich Schiller University, Jena, Germany | ||
| 14:30 | 42. | Antiviral Activity of (−)-Carbocyclic Cytosine [(−)-Carbodine] Against Venezuelan Equine Encephalitis Virus (VEEV) in a Mouse Model |
| Justin Julander1, Chung Chu2, Jagadeeshwar Rao2, Kristiina Shafer1, John Morrey1 | ||
| 1Institute for Antiviral Research, Utah State University; 2The University of Georgia College of Pharmacy | ||
| 14:45 | Late-breaker presentation | |
| 15:00 | Late-breaker presentation | |
| 15:15 | Late-breaker presentation | |
| 15:30 | Adjournment of the 20th ICAR | |